Q-omics provides the consensus-scored SETP16 profile across patient tissues and cancer cell-line models. SETP16 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SETP16 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, SETP16 RNA expression shows 6,717 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, THCA, and STAD as cancer lineages where SETP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SETP16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SETP16 survival associations across molecular data types. SETP16 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SETP16 RNA expression–survival associations across cancer types. High SETP16 expression shows unfavorable associations in UVM, UCEC, READ, THYM and ESCA, but favorable associations in CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SETP16 RNA expression.
This table summarizes SETP16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SETP16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SETP16 shows lower tumor expression in THCA and higher tumor expression in STAD and BRCA. The THCA box plot shows higher SETP16 RNA expression in normal versus tumor tissue (log2 FC = −0.081, t-test p = .027).
This table shows molecular features associated with SETP16 in patient tissues and cancer cell lines. In patient samples, SETP16 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
